Trending

cough

Merck & Co plans to file cough drug gefapixant after phase 3 success

Merck & Co plans to file cough drug gefapixant after phase 3 success

Merck & Co is planning to file a drug for unexplained or treatment-resistant cough after supportive results from

X

Merck & Co plans to file cough drug gefapixant after phase 3 success

https://pharmaphorum.com/news/merck-co-plans-to-file-cough-drug-gefapixant-after-phase-3-success/

Merck’s chronic cough drug gefapixant clears phase 3 test

Merck’s chronic cough drug gefapixant clears phase 3 test

Merck & Co/MSD’s experimental drug gefapixant has improved the frequency of coughing in a pair of phase 3

X

Merck’s chronic cough drug gefapixant clears phase 3 test

https://pharmaphorum.com/news/mercks-chronic-cough-drug-gefapixant-clears-phase-3-test/

Merck to buy Afferent in potential $1.25 bn deal

Merck to buy Afferent in potential $1.25 bn deal

Merck to develop cough drug.

X

Merck to buy Afferent in potential $1.25 bn deal

https://pharmaphorum.com/news/merck-buy-afferent-potential-1-25-bn-deal/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com